BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 35066662)

  • 21. Adjuvant SOX chemotherapy versus concurrent chemoradiotherapy after D2 radical resection of locally advanced esophagogastric junction (EGJ) adenocarcinoma: study protocol for a randomized phase III trial (ARTEG).
    Shen J; Zhu X; Du Y; Zhu Y; Yu P; Yang L; Xu Z; Huang L; Zhang Y; Zhang Y; Liu L; Cheng X
    Trials; 2021 Oct; 22(1):753. PubMed ID: 34717717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of S-1-based vs. capecitabine-based adjuvant chemotherapy for patients with gastric cancer: a systematic review and meta-analysis.
    Zhang Q; Qian Y; Yin Y
    Eur J Clin Pharmacol; 2021 Dec; 77(12):1791-1804. PubMed ID: 34275019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intraoperative radiotherapy combined with adjuvant chemoradiotherapy for locally advanced gastric adenocarcinoma.
    Fu S; Lu JJ; Zhang Q; Yang Z; Peng L; Xiong F
    Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1488-94. PubMed ID: 18538489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer versus curative resection alone: final results of the Japan Clinical Oncology Group trial JCOG9206-2.
    Miyashiro I; Furukawa H; Sasako M; Yamamoto S; Nashimoto A; Nakajima T; Kinoshita T; Kobayashi O; Arai K;
    Gastric Cancer; 2011 Aug; 14(3):212-8. PubMed ID: 21336855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant chemotherapy in locally advanced gastric cancer: what to avoid. Preliminary analysis of a consecutive series of patients.
    Rausei S; Lianos GD; Proserpio I; Ruspi L; Galli F; Frattini F; Mangano A; Rovera F; Boni L; Roukos DH; Pinotti G; Dionigi G
    Tumori; 2015; 101(5):511-6. PubMed ID: 25908036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): Chinese subgroup analysis].
    Ji J; Liang H; Zhan Y; Liu Y; He Y; Ye Y; Sun Y; Huang C; Yan M; Shi Y; Wu A
    Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Feb; 17(2):133-8. PubMed ID: 24577767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma: A National Cancer Data Base analysis.
    Stumpf PK; Amini A; Jones BL; Koshy M; Sher DJ; Lieu CH; Schefter TE; Goodman KA; Rusthoven CG
    Cancer; 2017 Sep; 123(17):3402-3409. PubMed ID: 28513823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage.
    Shin K; Park SJ; Lee J; Park CH; Song KY; Lee HH; Seo HS; Jung YJ; Park JM; Lee SH; Roh SY; Kim IH
    BMC Cancer; 2019 Dec; 19(1):1232. PubMed ID: 31852475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surgical resection of advanced gastric cancer following trastuzumab/oxaliplatin/capecitabine combination therapy.
    Dong CX; Fu JF; Ye XY; Li XF; Zhong X; Yuan Y
    World J Gastroenterol; 2014 Sep; 20(34):12355-8. PubMed ID: 25232273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination 5-fluoruracil/cisplatinum versus 5-fluoruracil/leucovorin adjuvant chemotherapy efficacy for R0 gastric resection in locally invasive gastric cancer.
    Yamada S; Ritchim P; Charkrabandhu T; Jongraksat W
    J Med Assoc Thai; 2012 Dec; 95(12):1517-23. PubMed ID: 23390781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intraarterial chemotherapy as an adjuvant treatment in locally advanced gastric cancer.
    Tentes AA; Markakidis SK; Karanikiotis C; Fiska A; Tentes IK; Manolopoulos VG; Dimitriou T
    Langenbecks Arch Surg; 2006 Apr; 391(2):124-9. PubMed ID: 16534653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute.
    Moon YW; Jeung HC; Rha SY; Yoo NC; Roh JK; Noh SH; Kim BS; Chung HC
    Ann Surg Oncol; 2007 Oct; 14(10):2730-7. PubMed ID: 17632757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison between better and poorly differentiated locally advanced gastric cancer in preoperative chemotherapy: a retrospective, comparative study at a single tertiary care institute.
    Sun LB; Zhao GJ; Ding DY; Song B; Hou RZ; Li YC
    World J Surg Oncol; 2014 Sep; 12():280. PubMed ID: 25200958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant Chemotherapy Versus Chemoradiotherapy Versus Surgery Alone for Early Gastric Cancer with One or Two Lymph Node Metastasis.
    Kim SM; An JY; Lee J; Sohn TS; Kim S
    Ann Surg Oncol; 2018 Jun; 25(6):1616-1624. PubMed ID: 29569127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study.
    Fuse N; Bando H; Chin K; Ito S; Yoshikawa T; Tsuburaya A; Terashima M; Kawashima Y; Fukunaga T; Gotoh M; Emi Y; Yoshida K; Oki E; Takahashi S; Kuriki H; Sato K; Sasako M
    Gastric Cancer; 2017 Mar; 20(2):332-340. PubMed ID: 26956689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Patients with Gastric Cancer After D2 Lymph Node Dissection: A Retrospective, Multi-Center Observational Study.
    Kim IH; Park SS; Lee CM; Kim MC; Kwon IK; Min JS; Kim HI; Lee HH; Lee SI; Chae H
    Ann Surg Oncol; 2018 May; 25(5):1176-1183. PubMed ID: 29450755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A case of gastric cancer showing response to first-line XP regimen after lymph node recurrence during the administration of S-1 as postoperative adjuvant chemotherapy].
    Mihara K; Yamashiro N; Nishiya S; Kemmochi T; Ito Y; Egawa T; Nagashima A
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2358-60. PubMed ID: 25731522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of National Adoption of Evidence-Based Treatment for Resectable Gastric Adenocarcinoma.
    Lee TC; Wima K; Morris MC; Johnston ME; Shah SA; Ahmad SA; Patel SH; Wilson GC
    J Gastrointest Surg; 2021 Jan; 25(1):36-47. PubMed ID: 33201456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer.
    Hwang JE; Kim H; Shim HJ; Bae WK; Hwang EC; Jeong O; Ryu SY; Park YK; Cho SH; Chung IJ
    J Cancer Res Clin Oncol; 2019 Aug; 145(8):2157-2166. PubMed ID: 31273512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.
    Fujitani K; Yang HK; Mizusawa J; Kim YW; Terashima M; Han SU; Iwasaki Y; Hyung WJ; Takagane A; Park DJ; Yoshikawa T; Hahn S; Nakamura K; Park CH; Kurokawa Y; Bang YJ; Park BJ; Sasako M; Tsujinaka T;
    Lancet Oncol; 2016 Mar; 17(3):309-318. PubMed ID: 26822397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.